Karyopharm Therapeutics Inc. (KPTI)Healthcare | Biotechnology | Newton, United States | NasdaqGS
0.39 USD
+0.04
(11.203%)
⇧
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 0.39 +0.00 (0.103%) ⇧ (Oct. 16, 2026, 6:59 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 4:28 a.m. EDT
The investment case for Karyopharm Therapeutics is currently broken by a perfect storm of deteriorating fundamentals and overwhelming market pessimism. The company is trapped in a multi-year structural decline, having lost 96% of its value over the last nine years with five consecutive years of negative annual returns. This is not a temporary setback; the market has consistently reassessed the business quality downward, evidenced by the relentless price drop from over $170 to under $1. The financial health is precarious, with negative earnings, negative free cash flow, and a balance sheet where debt far exceeds cash reserves. While the gross margin remains high, the operating burn is unsustainable without significant capital infusion or a miraculous catalyst. The recent private placement provides some liquidity, but it does not fix the core business problem of failing to generate revenue growth. Furthermore, the options market is screaming 'sell,' with put writers and buyers establishing heavy hedges against further drops while almost no one is betting on a rally. With no dividend to provide income and a trajectory that suggests the market sees no path to recovery soon, this is a security to avoid. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.373869 |
| MSTL | 0.402030 |
| AutoARIMA | 0.440499 |
| AutoETS | 0.440897 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 1.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.785 |
| Excess Kurtosis | -0.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 7.554 |
| Market Cap | 8,848,038 |
| Forward P/E | -0.14 |
| Beta | 1.04 |
| Profit Margins | -153.28% |
| Website | https://www.karyopharm.com |
As of Oct. 10, 2026, 4:28 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest dominates across nearly all expirations, with massive concentrations at strikes significantly below the current price (e.g., 7.5 and 10.0 strikes for November 2026 puts). Call activity is sparse and concentrated at very low strikes, indicating a lack of bullish conviction. Implied volatility is elevated for near-term puts relative to calls, suggesting fear of a continued decline.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9397218 |
| Address1 | 85 Wells Avenue |
| Address2 | 2nd Floor, Suite 210 |
| All Time High | 735.075 |
| All Time Low | 0.31 |
| Ask | 0.4457 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 1,457,890 |
| Average Daily Volume3 Month | 1,828,984 |
| Average Volume | 1,828,984 |
| Average Volume10Days | 1,457,890 |
| Beta | 1.037 |
| Bid | 0.328 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | -14.557 |
| City | Newton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.3901 |
| Current Ratio | 0.792 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.4 |
| Day Low | 0.33 |
| Display Name | Karyopharm Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,622,400 |
| Earnings Call Timestamp Start | 1,786,622,400 |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | -82,201,000 |
| Ebitda Margins | -0.56064 |
| Enterprise To Ebitda | -3.312 |
| Enterprise To Revenue | 1.857 |
| Enterprise Value | 272,273,024 |
| Eps Current Year | -5.845 |
| Eps Forward | -2.82 |
| Eps Trailing Twelve Months | -14.33 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.50706 |
| Fifty Day Average Change | -1.11696 |
| Fifty Day Average Change Percent | -0.74115163 |
| Fifty Two Week Change Percent | -93.97218 |
| Fifty Two Week High | 10.99 |
| Fifty Two Week High Change | -10.599899 |
| Fifty Two Week High Change Percent | -0.96450406 |
| Fifty Two Week Low | 0.31 |
| Fifty Two Week Low Change | 0.0801 |
| Fifty Two Week Low Change Percent | 0.2583871 |
| Fifty Two Week Range | 0.31 - 10.99 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,383,748,200,000 |
| Float Shares | 17,292,799 |
| Forward Eps | -2.82 |
| Forward P E | -0.13833334 |
| Free Cashflow | -29,674,250 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 228 |
| Fullday Change | 0.0397 |
| Fullday Change Percent | 11.31699 |
| Fullday Price | 0.3901 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.99061996 |
| Gross Profits | 145,246,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04671 |
| Held Percent Institutions | 0.95822996 |
| Implied Shares Outstanding | 22,681,460 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,740,528,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. |
| Long Name | Karyopharm Therapeutics Inc. |
| Market | us_market |
| Market Cap | 8,848,038 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_115373285 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -224,740,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 39,805,962 |
| Number Of Analyst Opinions | 4 |
| Open | 0.3509 |
| Operating Cashflow | -65,347,000 |
| Operating Margins | -0.67379 |
| Overall Risk | 8 |
| Phone | 617 658 0600 |
| Post Market Change | 0.00040000677 |
| Post Market Change Percent | 0.10253955 |
| Post Market Price | 0.3905 |
| Post Market Time | 1,792,191,562 |
| Previous Close | 0.3508 |
| Price Eps Current Year | -0.0667408 |
| Price Hint | 4 |
| Price To Book | -0.026798103 |
| Price To Sales Trailing12 Months | 0.060346324 |
| Profit Margins | -1.5328 |
| Quick Ratio | 0.708 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0393 |
| Regular Market Change Percent | 11.203 |
| Regular Market Day High | 0.4 |
| Regular Market Day Low | 0.33 |
| Regular Market Day Range | 0.33 - 0.4 |
| Regular Market Open | 0.3509 |
| Regular Market Previous Close | 0.3508 |
| Regular Market Price | 0.3901 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 2,690,656 |
| Return On Assets | -0.47612998 |
| Revenue Growth | -0.119 |
| Revenue Per Share | 7.554 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 22,681,460 |
| Shares Percent Shares Out | 0.26700002 |
| Shares Short | 6,056,162 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,813,744 |
| Short Name | Karyopharm Therapeutics Inc. |
| Short Percent Of Float | 0.2684 |
| Short Ratio | 4.17 |
| Source Interval | 15 |
| State | MA |
| Symbol | KPTI |
| Target High Price | 11.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 7.25 |
| Target Median Price | 7.5 |
| Total Cash | 65,105,000 |
| Total Cash Per Share | 2.87 |
| Total Debt | 328,529,984 |
| Total Revenue | 146,620,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -14.33 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.394215 |
| Two Hundred Day Average Change | -6.004115 |
| Two Hundred Day Average Change Percent | -0.9389917 |
| Type Disp | Equity |
| Volume | 2,690,656 |
| Website | https://www.karyopharm.com |
| Zip | 02,459-3298 |